Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Gross Profit (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Gross Profit data on record, last reported at $184194.0 in Q4 2025.

  • For Q4 2025, Gross Profit fell 60.04% year-over-year to $184194.0; the TTM value through Dec 2025 reached $1.3 million, down 21.65%, while the annual FY2025 figure was $1.7 million, 55.02% up from the prior year.
  • Gross Profit reached $184194.0 in Q4 2025 per INM's latest filing, down from $403159.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $1.6 million in Q2 2023 and bottomed at -$491018.0 in Q3 2022.
  • Average Gross Profit over 5 years is $314202.0, with a median of $249714.0 recorded in 2022.
  • The widest YoY moves for Gross Profit: up 2222.82% in 2024, down 70.32% in 2024.
  • A 5-year view of Gross Profit shows it stood at $111555.0 in 2021, then increased by 17.58% to $131163.0 in 2022, then surged by 147.13% to $324142.0 in 2023, then soared by 42.19% to $460894.0 in 2024, then plummeted by 60.04% to $184194.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $184194.0 in Q4 2025, $403159.0 in Q3 2025, and $576654.0 in Q2 2025.